Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis

John D. Lee, Nur A. Kamaruzaman, Jenny N T Fung, Stephen M. Taylor, Bradley J. Turner, Julie D. Atkin, Trent M. Woodruff, Peter G. Noakes

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Components of the innate immune complement system have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS); however, a comprehensive examination of complement expression in this disease has not been performed. This study therefore aimed to determine the expression of complement components (C1qB, C4, factor B, C3/C3b, C5 and CD88) and regulators (CD55 and CD59a) in the lumbar spinal cord of hSOD1G93A mice during defined disease stages.Methods: hSOD1G93A and wild-type mice were examined at four different ages of disease progression. mRNA and protein expression of complement components and regulators were examined using quantitative PCR, western blotting and ELISA. Localisation of complement components within lumbar spinal cord was investigated using immunohistochemistry. Statistical differences between hSOD1G93A and wild-type mice were analysed using a two-tailed t-test at each stage of disease progression.Results: We found several early complement factors increased as disease progressed, whilst complement regulators decreased; suggesting overall increased complement activation through the classical or alternative pathways in hSOD1G93A mice. CD88 was also increased during disease progression, with immunolocalisation demonstrating expression on motor neurons and increasing expression on microglia surrounding the regions of motor neuron death.Conclusions: These results indicate that local complement activation and increased expression of CD88 may contribute to motor neuron death and ALS pathology in the hSOD1G93A mouse. Hence, reducing complement-induced inflammation could be an important therapeutic strategy to treat ALS.

LanguageEnglish
Article number119
Pages1-14
Number of pages14
JournalJournal of Neuroinflammation
Volume10
DOIs
Publication statusPublished - 26 Sep 2013
Externally publishedYes

Fingerprint

Amyotrophic Lateral Sclerosis
Transgenic Mice
Spinal Cord
Motor Neurons
Disease Progression
Classical Complement Pathway
Complement C4
Alternative Complement Pathway
Complement Factor B
Complement Activation
Microglia
Immune System
Complement System Proteins
Western Blotting
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Pathology
Inflammation
Polymerase Chain Reaction
Messenger RNA

Cite this

Lee, John D. ; Kamaruzaman, Nur A. ; Fung, Jenny N T ; Taylor, Stephen M. ; Turner, Bradley J. ; Atkin, Julie D. ; Woodruff, Trent M. ; Noakes, Peter G. / Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. In: Journal of Neuroinflammation. 2013 ; Vol. 10. pp. 1-14.
@article{dd61734b8b1e44c8932f33c4c693f7f0,
title = "Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis",
abstract = "Background: Components of the innate immune complement system have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS); however, a comprehensive examination of complement expression in this disease has not been performed. This study therefore aimed to determine the expression of complement components (C1qB, C4, factor B, C3/C3b, C5 and CD88) and regulators (CD55 and CD59a) in the lumbar spinal cord of hSOD1G93A mice during defined disease stages.Methods: hSOD1G93A and wild-type mice were examined at four different ages of disease progression. mRNA and protein expression of complement components and regulators were examined using quantitative PCR, western blotting and ELISA. Localisation of complement components within lumbar spinal cord was investigated using immunohistochemistry. Statistical differences between hSOD1G93A and wild-type mice were analysed using a two-tailed t-test at each stage of disease progression.Results: We found several early complement factors increased as disease progressed, whilst complement regulators decreased; suggesting overall increased complement activation through the classical or alternative pathways in hSOD1G93A mice. CD88 was also increased during disease progression, with immunolocalisation demonstrating expression on motor neurons and increasing expression on microglia surrounding the regions of motor neuron death.Conclusions: These results indicate that local complement activation and increased expression of CD88 may contribute to motor neuron death and ALS pathology in the hSOD1G93A mouse. Hence, reducing complement-induced inflammation could be an important therapeutic strategy to treat ALS.",
author = "Lee, {John D.} and Kamaruzaman, {Nur A.} and Fung, {Jenny N T} and Taylor, {Stephen M.} and Turner, {Bradley J.} and Atkin, {Julie D.} and Woodruff, {Trent M.} and Noakes, {Peter G.}",
year = "2013",
month = "9",
day = "26",
doi = "10.1186/1742-2094-10-119",
language = "English",
volume = "10",
pages = "1--14",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "Springer, Springer Nature",

}

Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. / Lee, John D.; Kamaruzaman, Nur A.; Fung, Jenny N T; Taylor, Stephen M.; Turner, Bradley J.; Atkin, Julie D.; Woodruff, Trent M.; Noakes, Peter G.

In: Journal of Neuroinflammation, Vol. 10, 119, 26.09.2013, p. 1-14.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis

AU - Lee, John D.

AU - Kamaruzaman, Nur A.

AU - Fung, Jenny N T

AU - Taylor, Stephen M.

AU - Turner, Bradley J.

AU - Atkin, Julie D.

AU - Woodruff, Trent M.

AU - Noakes, Peter G.

PY - 2013/9/26

Y1 - 2013/9/26

N2 - Background: Components of the innate immune complement system have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS); however, a comprehensive examination of complement expression in this disease has not been performed. This study therefore aimed to determine the expression of complement components (C1qB, C4, factor B, C3/C3b, C5 and CD88) and regulators (CD55 and CD59a) in the lumbar spinal cord of hSOD1G93A mice during defined disease stages.Methods: hSOD1G93A and wild-type mice were examined at four different ages of disease progression. mRNA and protein expression of complement components and regulators were examined using quantitative PCR, western blotting and ELISA. Localisation of complement components within lumbar spinal cord was investigated using immunohistochemistry. Statistical differences between hSOD1G93A and wild-type mice were analysed using a two-tailed t-test at each stage of disease progression.Results: We found several early complement factors increased as disease progressed, whilst complement regulators decreased; suggesting overall increased complement activation through the classical or alternative pathways in hSOD1G93A mice. CD88 was also increased during disease progression, with immunolocalisation demonstrating expression on motor neurons and increasing expression on microglia surrounding the regions of motor neuron death.Conclusions: These results indicate that local complement activation and increased expression of CD88 may contribute to motor neuron death and ALS pathology in the hSOD1G93A mouse. Hence, reducing complement-induced inflammation could be an important therapeutic strategy to treat ALS.

AB - Background: Components of the innate immune complement system have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS); however, a comprehensive examination of complement expression in this disease has not been performed. This study therefore aimed to determine the expression of complement components (C1qB, C4, factor B, C3/C3b, C5 and CD88) and regulators (CD55 and CD59a) in the lumbar spinal cord of hSOD1G93A mice during defined disease stages.Methods: hSOD1G93A and wild-type mice were examined at four different ages of disease progression. mRNA and protein expression of complement components and regulators were examined using quantitative PCR, western blotting and ELISA. Localisation of complement components within lumbar spinal cord was investigated using immunohistochemistry. Statistical differences between hSOD1G93A and wild-type mice were analysed using a two-tailed t-test at each stage of disease progression.Results: We found several early complement factors increased as disease progressed, whilst complement regulators decreased; suggesting overall increased complement activation through the classical or alternative pathways in hSOD1G93A mice. CD88 was also increased during disease progression, with immunolocalisation demonstrating expression on motor neurons and increasing expression on microglia surrounding the regions of motor neuron death.Conclusions: These results indicate that local complement activation and increased expression of CD88 may contribute to motor neuron death and ALS pathology in the hSOD1G93A mouse. Hence, reducing complement-induced inflammation could be an important therapeutic strategy to treat ALS.

UR - http://www.scopus.com/inward/record.url?scp=84884538493&partnerID=8YFLogxK

U2 - 10.1186/1742-2094-10-119

DO - 10.1186/1742-2094-10-119

M3 - Article

VL - 10

SP - 1

EP - 14

JO - Journal of Neuroinflammation

T2 - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

M1 - 119

ER -